4-[5-[2-(4-Nitrophenyl)-2-oxoethyl]sulfanyltetrazol-1-yl]benzoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[5-[2-(4-Nitrophenyl)-2-oxoethyl]sulfanyltetrazol-1-yl]benzoic acid
• 化学式: C16H11N5O5S
• 分子量: 385.4
• InChiKey: NYIQVTKVZCHUAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  169
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS
  申请人：Fundación Profesor Novoa Santos

  公开号：EP3653208A1

  公开（公告）日：2020-05-20

  The present invention provides a class of compounds, which includes enantiomers and pharmaceutically acceptable salts thereof, that selectively and effectively inhibit Hakai-mediated ubiquitination, preferably without affecting Hakai protein levels, thereby representing excellent anti-cancer drugs useful in the treatment of a variety of cancers, such as carcinomas, in particular, tumors arising from the epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer). It also includes skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).

  本发明提供了一类化合物，其中包括对映体和其药学上可接受的盐，能够选择性和有效地抑制Hakai介导的泛素化，优选地不影响Hakai蛋白水平，因此代表了出色的抗癌药物，可用于治疗多种癌症，特别是从胃肠道上皮层发生的肿瘤，包括口腔癌、食管癌、胃癌、小肠和大肠（如直肠或结肠癌），还包括皮肤癌、乳腺癌、胰腺癌、肺癌、头颈癌、肝癌、卵巢癌、宫颈癌、子宫癌、胆囊癌、阴茎癌和泌尿膀胱癌（如肾、前列腺或膀胱癌）。
• UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Fundación Profesor Novoa Santos

  公开号：EP3909577A1

  公开（公告）日：2021-11-17

  The present invention relates to a novel class of compounds and to compositions comprising the same as well as their used as medicaments in the treatment of cancer.

  本发明涉及一类新型化合物和包含这些化合物的组合物，以及它们在治疗癌症中的用途。
• US9757375B2
  申请人：——

  公开号：US9757375B2

  公开（公告）日：2017-09-12
• [EN] COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS<br/>[FR] COMPOSÉS QUI INHIBENT SÉLECTIVEMENT ET EFFICACEMENT L'UBIQUITINATION MÉDIÉE PAR HAKAI, EN TANT QUE MÉDICAMENTS ANTICANCÉREUX
  申请人：FUND PROFESOR NOVOA SANTOS

  公开号：WO2020099652A1

  公开（公告）日：2020-05-22

  The present invention provides a class of compounds, which includes enantiomers and pharmaceutically acceptable salts thereof, that selectively and effectively inhibit Hakai-mediated ubiquitination, preferably without affecting Hakai protein levels, thereby representing excellent anti-cancer drugs useful in the treatment of a variety of cancers, such as carcinomas, in particular, tumors arising from the epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer). It also includes skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).
• [EN] UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] INHIBITEURS D'UBIQUITINE-LIGASE POUR LE TRAITEMENT DU CANCER
  申请人：[en]FUNDACIÓN PROFESOR NOVOA SANTOS

  公开号：WO2021229035A1

  公开（公告）日：2021-11-18

  The present invention relates to a novel class of compounds and to compositions comprising the same as well as their used as medicaments in the treatment of cancer.